Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20202854 | 1.00 | LRRK2 (0.34) | LRRK2SSTR4CYP2D6CYP2C9GRIN2B | |
| SCHEMBL20202819 | 1.00 | LRRK2 (0.34) | LRRK2SSTR4CYP2D6CYP2C9GRIN2B | |
| Trifluoroacetic Acid SCHEMBL20189426 | 0.89 | HRH4 (0.39) | SSTR4CYP2D6CYP2C9GRIN2BKEAP1 | |
| Trifluoroacetic Acid SCHEMBL20189794 | 0.89 | HRH4 (0.39) | SSTR4CYP2D6CYP2C9GRIN2BKEAP1 | |
| SCHEMBL20189870 | 0.81 | GRIN2B (0.36) | LRRK2SSTR4CYP2D6CYP2C9GRIN2B | |
| SCHEMBL20189872 | 0.81 | GRIN2B (0.36) | LRRK2SSTR4CYP2D6CYP2C9GRIN2B | |
| SCHEMBL20189590 | 0.80 | LRRK2 (0.39) | LRRK2GRIN2B | |
| SCHEMBL20189588 | 0.80 | LRRK2 (0.39) | LRRK2GRIN2B | |
| SCHEMBL18296935 | 0.78 | GRIN2B (0.40) | LRRK2SSTR4GRIN2B | |
| SCHEMBL20189218 | 0.78 | GRIN2B (0.40) | LRRK2SSTR4GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2023-09-12 | — | — | US | disclosed |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2023-09-12 | — | — | US | disclosed |
| US-20210220365-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2021-07-22 | — | — | US | disclosed |
| US-11000526-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2021-05-11 | — | — | US | disclosed |
| US-20190298725-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-10-03 | — | — | US | disclosed |
| WO-2018098128-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000526-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2A, GRIN1, GRIN2B | LRRK2 876/4885SSTR4 1317/4885CYP2D6 3997/4885 |
| US-20190298725-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | GRIN2A, GRIN1, GRIN2B | LRRK2 876/4885SSTR4 1317/4885CYP2D6 3997/4885 |
| US-20210220365-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | GRIN2A, GRIN1, GRIN2B | LRRK2 876/4885SSTR4 1317/4885CYP2D6 3997/4885 |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2A, GRIN1, GRIN2B | LRRK2 876/4885SSTR4 1317/4885CYP2D6 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.